Penumbra Inc (NYSE:PEN) Director Thomas Wilder sold 345 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $91.15, for a total transaction of $31,446.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Penumbra Inc (NYSE PEN) opened at $101.60 on Tuesday. The company has a market cap of $3,450.00 and a price-to-earnings ratio of 483.81. Penumbra Inc has a one year low of $67.95 and a one year high of $116.35.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.07. The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The business’s quarterly revenue was up 24.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) EPS. analysts expect that Penumbra Inc will post -0.15 earnings per share for the current year.

PEN has been the subject of several recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $113.00 target price on shares of Penumbra in a report on Wednesday, January 24th. BMO Capital Markets reiterated a “buy” rating and issued a $96.00 price target on shares of Penumbra in a research note on Friday, October 13th. Zacks Investment Research upgraded shares of Penumbra from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, JPMorgan Chase & Co. cut shares of Penumbra from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $111.50.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of Penumbra by 1.2% during the 2nd quarter. FMR LLC now owns 5,042,974 shares of the company’s stock valued at $442,521,000 after buying an additional 57,801 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Penumbra by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock valued at $190,066,000 after buying an additional 47,768 shares in the last quarter. BlackRock Inc. raised its position in shares of Penumbra by 4.7% during the 2nd quarter. BlackRock Inc. now owns 1,815,299 shares of the company’s stock valued at $159,294,000 after buying an additional 81,981 shares in the last quarter. Lord Abbett & CO. LLC raised its position in shares of Penumbra by 5.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 1,093,621 shares of the company’s stock valued at $95,965,000 after buying an additional 53,109 shares in the last quarter. Finally, State Street Corp raised its position in shares of Penumbra by 13.2% during the 2nd quarter. State Street Corp now owns 579,911 shares of the company’s stock valued at $50,887,000 after buying an additional 67,441 shares in the last quarter. Hedge funds and other institutional investors own 71.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Thomas Wilder Sells 345 Shares of Penumbra Inc (NYSE:PEN) Stock” was originally reported by Marea Informative and is the property of of Marea Informative. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.mareainformativa.com/2018/01/30/penumbra-inc-pen-director-sells-31446-75-in-stock-updated-updated-updated.html.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.